Pfizer Inc. is a global biopharmaceutical company headquartered in New York City, founded in 1849 by cousins Charles Pfizer and Charles Erhart. Over more than 170 years, Pfizer has evolved from a fine chemicals manufacturer into one of the world’s largest pharmaceutical organizations. The company operates in over 125 countries and maintains research and development facilities, manufacturing sites, and commercial offices across North America, Europe, Latin America, Asia and Africa.
Pfizer’s core business centers on the discovery, development, manufacturing and commercialization of prescription medicines and vaccines. Its broad portfolio spans multiple therapeutic areas, including oncology, immunology, cardiology, endocrinology, rare diseases and infectious diseases. Notable products have included the lipid-lowering agent Lipitor, the anti-inflammatory Xeljanz, and the COVID-19 vaccine Comirnaty developed in collaboration with BioNTech.
Research and innovation remain foundational to Pfizer’s strategy, with significant annual investment directed toward its pipeline of small molecules, biologics and gene therapies. The company has grown through key acquisitions such as Wyeth in 2009 and Hospira in 2015, and it maintains partnerships with academic institutions and biotechnology firms to accelerate the development of novel treatments. Pfizer also engages in licensing agreements and joint ventures to expand its consumer healthcare and specialty care offerings.
Since January 2019, Pfizer has been led by Chairman and Chief Executive Officer Albert Bourla, under whose leadership the company has prioritized next-generation vaccine platforms, precision medicine and sustainable manufacturing practices. With a focus on meeting global health challenges, Pfizer continues to pursue regulatory approvals, global market expansion and initiatives aimed at improving patient access to its medicines and vaccines.